Evidence map›Paper›PMID 42003684›Full record

ArticleBJU international2026

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

Alexandra S Bruins Slot, Vera Sweere, Joris G Heetman, Rick Hermsen, Lieke Wever, Jules Lavalaye, Maarten Vinken, Clinton D Bahler, Mark Tann, Claudia Kesch and 22 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Alexandra S Bruins SlotDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.ORCID https://orcid.org/0009-0001-9991-6988
Vera SweereDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Joris G HeetmanDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Rick HermsenDepartment of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Lieke WeverDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Jules LavalayeDepartment of Nuclear Medicine, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Maarten VinkenDepartment of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Clinton D BahlerDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0003-0484-801X
Mark TannDepartment of Radiology and Imaging Sciences, Indiana University Medical Center, Indianapolis, IN, USA.
Claudia KeschDepartment of Urology, University Hospital Essen, Essen German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany.
Tugce TelliDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Peter Ka-Fung ChiuS. H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0000-0002-1499-8372
Kwan Kit WuDepartment of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Fabio ZattoniUrological Unit, Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Francesco CeciDivision of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Marcin MiszczykDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Pawel RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-4073-6584
Akihiro MatsukawaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-3324-762X
Tamás FazekasDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Francesco BarlettaDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Alberto BrigantiDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Francesco MontorsiDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID https://orcid.org/0000-0002-7267-4181
Giorgio GandagliaDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID https://orcid.org/0000-0002-5052-721X
Jean-Paul A Van BastenDepartment of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Harm H E Van MelickDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Roderick C N Van den BerghDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Giancarlo MarraDivision of Urology, Department of Surgical Sciences, Molinette Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy.
Timo F W SoeterikDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Matthijs J V ScheltemaDepartment of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
European Association of Urology‐Young Academic Urologists (EAU‐YAU) Prostate Cancer Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate whether nodal maximum standardised uptake value (SUV PATIENTS AND

methodsThis international multicentre study included patients with histopathologically confirmed PCa who underwent preoperative PSMA-PET and robot-assisted radical prostatectomy with extended pelvic lymph node dissection (2016-2023). Sensitivity, specificity, PPV, and negative predictive value (NPV) for LNI detection were calculated, defining a positive test as non-physiological PSMA uptake classified according to the Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) molecular imaging Tumour-Node-Metastasis (miTNM) system. Receiver operating curves analysis identified optimal nodal SUV

resultsA total of 521 patients were included, with a median (interquartile range) age of 66 (61-71) years and prostate-specific antigen (PSA) level of 9.9 (6.6-17.0) ng/mL. The PSMA-PET showed 45.0% sensitivity, 94.3% specificity, 64.7% PPV, and 88.3% NPV for LNI detection. Adding nodal SUV

conclusionNodal SUV

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IILymphatic MetastasisLymph NodesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansLymph Node ExcisionMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProstatectomySensitivity and SpecificityAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIhigh‐volume nodal diseaselymph node invasionmaximum standardised uptake valueprostatectomyProstate‐specific membrane antigen‐positron emission tomography/computerised tomographystaging

Identifiers

PMID42003684
PMCPMC13244919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.